0001140361-18-032008.txt : 20180710 0001140361-18-032008.hdr.sgml : 20180710 20180710131155 ACCESSION NUMBER: 0001140361-18-032008 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180706 FILED AS OF DATE: 20180710 DATE AS OF CHANGE: 20180710 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sofia Michael J. CENTRAL INDEX KEY: 0001635324 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34949 FILM NUMBER: 18946570 MAIL ADDRESS: STREET 1: C/O ONCORE BIOPHARMA, INC. STREET 2: 3805 OLD EASTON ROAD CITY: DOYLESTOWN STATE: PA ZIP: 18902 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Arbutus Biopharma Corp CENTRAL INDEX KEY: 0001447028 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 980597776 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100-8900 GLENLYON PARKWAY CITY: BURNABY STATE: A1 ZIP: V5J 5J8 BUSINESS PHONE: 604-419-3200 MAIL ADDRESS: STREET 1: 100-8900 GLENLYON PARKWAY CITY: BURNABY STATE: A1 ZIP: V5J 5J8 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS Corp DATE OF NAME CHANGE: 20110607 FORMER COMPANY: FORMER CONFORMED NAME: TEKMIRA PHARMACEUTICALS CORP DATE OF NAME CHANGE: 20081003 4 1 doc1.xml FORM 4 X0306 4 2018-07-06 0 0001447028 Arbutus Biopharma Corp ABUS 0001635324 Sofia Michael J. C/O ARBUTUS BIOPHARMA CORP. SUITE 100, 8900 GLENLYON PARKWAY BURNABY A1 V5J 5J8 BRITISH COLUMBIA, CANADA 0 1 0 0 Chief Scientific Officer Common Shares 2018-07-06 4 S 0 10000 8.45 D 1523403 D Common Shares 2018-07-09 4 S 0 10000 8.906 D 1513403 D Common Shares 171412 I Held by Irrevocable Deed of Trust of Michael J. Sofia dated December 22, 2014 (the "Trust") The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2017. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.50 to $9.35, inclusive. The reporting person undertakes to provide to Arbutus Biopharma Corp., any security holder of Arbutus Biopharma Corp., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the rages set forth in this footnote. /s/ David C. Hastings, as attorney-in-fact for Michael J. Sofia 2018-07-10